Quetiapin HEXAL

Quick links

Choose a section

Quick links to important sections

Advertisements

Quetiapin HEXAL

Advertisements
Advertisements
Advertisements

Overview of Quetiapin HEXAL

Quick Facts

Property Description
Active ingredient Quetiapine (as fumarate salt)
Form Oral tablets (Immediate-release and Prolonged-release)
Pharmacological class Atypical Antipsychotic (Second-generation)
Common purpose Modulating key neurotransmitters to promote neurological stability
Origin Synthetic (Dibenzothiazepine derivative)

What Type of Medicine is Quetiapin HEXAL?

Quetiapin HEXAL is a prescription-only pharmaceutical product containing the active substance quetiapine, a synthetic compound that is clinically recognized as an atypical antipsychotic agent. It belongs to the broader category of psychotropic agents used to help stabilize major central nervous system dysfunctions. The drug is chemically derived from the dibenzothiazepine class of substances.

The medicine is designated as a second-generation antipsychotic, a classification based on its ability to influence the activity of multiple neurotransmitters, notably dopamine and serotonin. Quetiapin HEXAL is one of the generic preparations of quetiapine fumarate, marketed by the manufacturer HEXAL AG to ensure broad patient access to this standard medication used for neurological stabilization.


Composition and Available Forms of Quetiapine

The composition of this medication is that of a monocomponent product, meaning it contains a single active ingredient, quetiapine fumarate, alongside necessary excipients in the solid dosage form. The product is supplied for oral administration in two distinct formats: the immediate-release (IR) film-coated tablets and the prolonged-release (PR or XR) tablets.

The prolonged-release formulation is a key distinction, as it is engineered to release the quetiapine gradually over a sustained period. This distinction in kinetic profile allows for consistent drug levels and supports varying clinical requirements for systemic exposure.


How Does Quetiapine Fumarate Affect Brain Chemistry?

Quetiapine fumarate affects brain chemistry by acting as an antagonist at several receptors in the central nervous system, meaning it modulates the activity of chemical messengers, predominantly dopamine and serotonin. This core mechanism involves the substance influencing the D2 dopamine receptors and the 5-HT2A serotonin receptors, among others.

By modulating these pathways, Quetiapine helps to alleviate irregular neuronal activity associated with psychiatric conditions. This action is recognized in clinical practice to promote neurological equilibrium, assisting in the regulation of emotional and thought processes.

Regulatory References

  1. Seroquel EPAR Summary
Advertisements

What side effects are possible with Quetiapin HEXAL?

Possible Side Effects and Safety Information

The safety profile of Quetiapin HEXAL is characterized by adverse reactions classified according to their official frequency and the physiological system affected, as documented by regulatory agencies.

Key effects are categorized based on their official incidence rate:

Frequency Classification Examples of Officially Listed Adverse Reactions
Very Common (ge 1/10) Somnolence, Dizziness, Dry mouth, Increased weight, Postural hypotension.
Common (ge 1/100) Tachycardia, Constipation, Hyperglycemia, Leukopenia, Increased liver enzymes.
Uncommon (ge 1/1,000) Seizures/Convulsions, Tardive Dyskinesia, QT Prolongation, Hypothyroidism.
Rare (ge 1/10,000) Neuroleptic Malignant Syndrome (NMS), Agranulocytosis, Priapism, Intestinal obstruction.

Serious adverse reactions officially documented include Neuroleptic Malignant Syndrome (NMS), severe Metabolic Changes (such as marked hyperglycemia and dyslipidemia), and a risk of severe reductions in white blood cell counts (Agranulocytosis/Neutropenia).

Population-Specific Safety Notes: An increased risk of mortality is documented when this medicine is used in older adults with dementia-related psychosis. For children and adolescents, there is a higher incidence of increased blood pressure.

Time-Related Safety Patterns: Orthostatic hypotension and somnolence are most frequently reported during the initial phase of treatment. Conversely, the potential for Tardive Dyskinesia and Cataracts is associated with long-term exposure.

Safety Monitoring: Due to potential risks, the official safety profile includes the requirement for baseline and periodic monitoring of weight, fasting blood glucose, and lipids. Frequent blood count monitoring is also required for patients with a history of low white blood cell count.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose with quetiapine is officially characterized by an exaggeration of its known pharmacological effects, specifically impacting the central nervous system (CNS) and cardiovascular system. The immediate necessity for medical intervention is due to the potential for severe, life-threatening outcomes, including reported cases of coma, respiratory depression, and death.

Documented Manifestations

Officially documented clinical signs include severe somnolence, profound sedation, and altered mental status, which may progress to confusion, delirium, and coma. Cardiovascular effects officially listed are tachycardia (fast heart rate) and hypotension (low blood pressure), alongside the critical risk of QTc prolongation, which can lead to severe cardiac arrhythmias. Patients with pre-existing severe cardiovascular disease are noted in regulatory documents to be at an increased risk of severe effects from overdose.

Required Emergency Actions

Immediate medical attention must be sought for any suspected or confirmed overdose. Official guidance mandates that patients receive symptomatic and supportive treatment under close medical supervision, with continuous cardiovascular monitoring, including electrocardiography (ECG), being required.

No specific antidote is known for quetiapine overdose. Management focuses on maintaining vital functions, such as ensuring airway patency. Regulatory guidance for treating associated hypotension specifies avoiding the use of epinephrine and dopamine, as these agents may aggravate the low blood pressure.

Advertisements

Therapeutic Uses of Quetiapin HEXAL

What Quetiapin HEXAL Treats: Main Uses and Benefits

The medication is commonly used to help with symptomatic support during episodes of heightened distress across psychiatric conditions. The medicine is commonly used across conditions presenting with acute episodes and recurrent manifestations in three primary areas, which is relevant when supportive symptom management is appropriate.

Symptom Management and Therapeutic Focus

Quetiapin HEXAL is commonly used to help manage the symptom clusters of Schizophrenia, both the positive symptoms (e.g., hallucinations, delusions) and negative symptoms (e.g., apathy), and Bipolar Disorder, specifically controlling manic episodes and providing relief for bipolar depressive episodes. Furthermore, it is commonly used as an adjunct therapy (add-on support) for adults with Major Depressive Disorder (MDD) who have experienced an inadequate response to initial treatment.

“The treatment approach is focused on easing the overall symptom load and supporting patients during difficult episodes by easing distress.”

In clinical settings that involve acute or unstable symptom patterns, the medication is applied across domains where additional symptomatic support is needed. This provides support that helps ease the overall symptom burden, and may assist with managing symptoms that interfere with daily functioning and maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Key Symptom Patterns
Bipolar Mania: Helps control high energy, impulsivity, and severe mood elevation.
Psychosis: Supports the management of severe thought and perceptual disturbances.
Depression: Contributes to easing persistent low mood when used as adjunct therapy.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quetiapin HEXAL — Official Regulatory Information

The eligibility profile for Quetiapin HEXAL is strictly defined by regulatory documentation concerning age, physiological state, and specific comorbidities.

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults (18+): Approved for all primary indications. Adolescents (13-17): Approved for Schizophrenia. Children and Adolescents (10-17): Approved for Bipolar I Disorder (manic or mixed episodes).
Populations for whom use is contraindicated Patients with Known Hypersensitivity to quetiapine or any formulation excipient. Patients receiving concomitant strong inhibitors of CYP3A4 (as formally classified in the SmPC).
Age-related eligibility rules Not Approved for use in pediatric patients under 10 years of age. Elderly Patients (General): Eligibility is conditional, requiring careful monitoring.
Condition-specific eligibility rules Hepatic Impairment: Conditional use required; lower starting dose and slower adjustment is necessary. Renal Impairment: Dosage adjustment is generally not necessary.
Pregnancy and lactation eligibility status Pregnancy: Conditional use; permitted only if the potential benefit justifies the potential risk. Lactation: Status requires discontinuation of the drug or nursing.

Eligibility-Related Restrictions

The medicine is explicitly not approved for the treatment of elderly patients with dementia-related psychosis due to a mandated Boxed Warning regarding increased mortality risk. Continued eligibility requires frequent complete blood count (CBC) monitoring for patients with a pre-existing low white cell count and regular metabolic monitoring (glucose, lipids, weight) for at-risk populations.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Information

The interaction profile for quetiapine is characterized by three main regulatory domains: metabolic modification, pharmacodynamic additive effects, and specific administration constraints.

Metabolic Interactions (Pharmacokinetic)

The medicine is cleared primarily by the CYP3A4 enzyme, leading to clinically significant pharmacokinetic interactions. Strong CYP3A4 inhibitors are contraindicated by some regulatory authorities (e.g., EMA) as they significantly increase quetiapine plasma levels by reducing clearance. Examples of such inhibitors include azole-antifungal agents, HIV-protease inhibitors, and nefazodone. Conversely, co-administration with strong CYP3A4 inducers, such as phenytoin, rifampin, and the herbal product St. John’s Wort, substantially decreases quetiapine exposure.

Pharmacodynamic and Other Constraints

Official documents advise caution with medicines that have overlapping effects. Combining quetiapine with Centrally Acting Drugs or alcohol (ethanol) carries a documented risk of additive central nervous system depression. Caution is also required with antihypertensive agents and other QTc-prolonging agents. A specific drug-food interaction is documented for the prolonged-release (XR) tablets, which must be taken without food or with a light meal to avoid a documented increase in systemic exposure. Individuals with hepatic impairment have an altered interaction profile and require a cautious, specific titration schedule.

Advertisements

Mechanism of Action

The function of Quetiapine is defined by a distinct pharmacological profile involving the modulation of multiple neurotransmitter systems in the central nervous system. Its mechanism of action is primarily achieved through complex interactions with specific receptors and transporters.


Differential Receptor Antagonism and Regulation

Quetiapine acts by antagonizing (blocking) the Serotonin 5 -HT2 A receptor with high affinity and the Dopamine D2 receptor with lower, transient affinity. This differential targeting rebalances the signaling activity of these two core chemical messengers, resulting in regulation of neural pathway activity in brain circuits governing communication.


Atypical Kinetics and Active Metabolite Synergy

The D2 receptor interaction is characterized by rapid dissociation, a kinetic mechanism that allows the resulting physiological effect to occur without sustained suppression of dopamine pathways. Furthermore, the active metabolite, Norquetiapine, extends the drug's effect by acting as a norepinephrine transporter inhibitor and a 5 -HT1 A partial agonist, synergistically contributing to the overall central monoamine tone.


Ancillary Pathway Modulation

The drug also strongly blocks the Histamine H1 and Adrenergic alpha1 receptors. These actions modulate systems governing central arousal and peripheral vascular tone, leading to a generalized central sedative state and physiological adjustments in vascular control that occur alongside the core neurotransmitter modulation.

Advertisements

Dosage and Administration Information

Quetiapin HEXAL is used exclusively by the oral route. The administration approach is specific to the formulation, which includes Immediate-Release (IR) tablets and Prolonged-Release (PR or XR) tablets. The IR formulation is typically administered twice daily and may be taken irrespective of food. The PR formulation, however, is intended for once-daily use, preferably in the evening, and must be taken without food or with only a light meal (approximately 300 calories or less).

A crucial usage instruction for the prolonged-release tablets is the requirement to swallow the tablet whole; it must not be split, chewed, or crushed, as this would interfere with the controlled-release mechanism.

Treatment initiation involves a gradual titration phase over the first several days, where the dose is slowly increased to reach the appropriate maintenance dose range. The maintenance dose is condition-dependent: for example, the dose for Bipolar Depression is usually fixed at 300 mg per day, while doses for Schizophrenia or Bipolar Mania may range from 400 mg up to a maximum of 800 mg daily.

Usage adjustments are applied for certain populations. Older adults and individuals with hepatic impairment initiate treatment with a lower starting dose (e.g., 25 mg or 50 mg per day) and proceed with a slower titration schedule. If a dose is missed, the standard approach is to skip the missed dose and take the next dose at the regularly scheduled time, rather than taking two doses to compensate.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Quetiapin HEXAL

The research base for this medicine includes structured clinical trials, which were designed to observe patterns and changes in symptoms under controlled conditions. The evidence describes the circumstances under which the medicine was studied and the outcomes that were measured, providing context but not individual predictions.


Evidence for Use in Schizophrenia

The initial evidence was developed through short-term randomized controlled trials (RCTs). These trials were used in research exploring how symptoms change over time in patients with conditions characterized by fluctuating or episodic manifestations, focusing on standardized measurements of both positive and negative symptom clusters. Longer maintenance trials were also conducted, applied in studies examining patient experiences with the aim focused on observing symptom recurrence in patients who were stable at the start of the study.


Evidence for Use in Bipolar Disorder

The research for its use in Bipolar Disorder includes research on both symptom measurement during acute phases and long-term follow-up. Studies were applied in research contexts involving fluctuating or unstable symptoms, monitoring outcomes related to systemic or functional imbalance. Studies explored short-term symptom changes in acute mania and acute depression, tracking changes in standardized rating scales. Long-term research examined outcomes related to recurrence patterns over periods that was observed in some studies up to two years.


Evidence for Adjunctive Use in Major Depressive Disorder (MDD)

Research examined short-term (6-week) placebo-controlled RCTs for use as an add-on treatment for adults who have experienced an inadequate response to their initial antidepressant treatment. Findings indicate patterns of measured score changes were observed in the study populations over the acute period. However, there is limited information for long-term outcomes when used specifically as an adjunctive treatment for MDD.


Evidence in Specific Patient Groups

Research has explored a limited number of studies including adolescents (13–17 years) for Schizophrenia and acute Bipolar Mania. Data for certain groups remain insufficient, notably for bipolar depressive episodes in patients over 65 years, meaning dedicated evidence for this use is lacking in this older age group. While the evidence contributes to the broader understanding of symptom patterns, regulatory reviews highlight areas where research is ongoing and certainty remains low, particularly regarding the lack of comprehensive long-term outcomes data.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Quetiapin HEXAL (FAQ)


Q: Is Quetiapin HEXAL considered a sleeping pill or an antipsychotic?

Quetiapine is formally classified by regulatory authorities as an atypical antipsychotic agent. It works by modulating specific chemical messengers in the brain. However, due to its action on certain receptors, including strong blocking of the Histamine H1 receptor, the medication can produce a sedative state and drowsiness. This sedative effect is a common reason why patients might perceive it as a sleep aid.


Q: How quickly does Quetiapin HEXAL start working for mood stabilization?

Official product information describes a gradual titration phase over the first several days, during which the dose is slowly increased to reach the maintenance level. While certain effects like sedation may be felt quickly, mood stabilization is an outcome observed over the course of treatment. The time frame for the full therapeutic benefit may vary depending on the condition being treated, such as acute mania or depression, as studied in clinical trials.


Q: Do you get withdrawal symptoms if you stop taking Quetiapin HEXAL abruptly?

Regulatory documents caution that acute withdrawal symptoms have been reported following the abrupt discontinuation of high doses of quetiapine. These symptoms can include effects like nausea, vomiting, difficulty sleeping, headaches, and irritability. Regulatory documents indicate that gradual discontinuation is often recommended to help minimize the potential for withdrawal effects.


Q: Does Quetiapin HEXAL cause weight gain, and if so, how significant is it typically?

Official safety data lists increased weight as a very common side effect associated with quetiapine use, and it is part of the required metabolic monitoring for patients. This potential for weight gain is noted across different populations in the product labeling. However, the specific amount or degree of weight gain can vary widely from person to person.


Q: Is it safe to take Quetiapin HEXAL with common antidepressants?

Quetiapine is sometimes used as an add-on treatment for Major Depressive Disorder (MDD) when the initial antidepressant treatment is not fully effective. However, regulatory documents advise caution when combining quetiapine with all medications that act on the central nervous system (CNS). This caution is due to the potential risk of additive effects, such as increased sedation or CNS depression.


Q: Can taking Quetiapin HEXAL make you feel more tired during the day?

Yes, somnolence (drowsiness or sleepiness) is listed as a Very Common side effect in official safety information. This effect is often reported most frequently during the initial phase of treatment as the body adjusts to the medication.


Q: Can Quetiapin HEXAL affect my ability to drive or operate machinery?

Official warnings state that quetiapine can cause side effects like somnolence (drowsiness), dizziness, and may impair coordination. The official label suggests that due to the potential for impairment, patients should exercise caution regarding driving or operating hazardous machinery until they know how the medication affects their cognitive and motor function.


Q: What should I do if I feel dizzy or lightheaded after taking Quetiapin HEXAL?

Dizziness and Postural hypotension (a drop in blood pressure when moving from sitting or lying to standing, which causes lightheadedness) are listed as Very Common side effects, especially when starting treatment. This side effect is generally related to Postural hypotension. Regulatory information highlights the importance of caution when changing body positions.


Q: Can Quetiapin HEXAL be prescribed for conditions other than schizophrenia or bipolar disorder?

The official product label details approved uses for Schizophrenia, Bipolar Disorder (manic and depressive episodes), and as an add-on treatment for Major Depressive Disorder (MDD). Any other potential use is not detailed or endorsed within the formal regulatory text that dictates the official indications for the medicine.


Q: Will taking Quetiapin HEXAL affect my body temperature regulation?

Official warnings note that quetiapine may disrupt the body's ability to lower core body temperature. Official warnings indicate that caution may be necessary when patients are exposed to conditions that increase body temperature, such as intense exercise or extreme heat.


Q: Can Quetiapin HEXAL cause changes in appetite?

Yes, along with the potential for weight gain, official safety data also lists increased appetite as an adverse reaction. This change in appetite may contribute to the overall metabolic changes associated with the medication.


Q: Why is it advised to avoid alcohol completely while taking Quetiapin HEXAL?

Regulatory documents explicitly advise against combining quetiapine with alcohol (ethanol) because of the risk of additive central nervous system (CNS) depression. This combination can lead to increased sedation, dizziness, and impairment beyond what is caused by either substance alone.


Q: How long does Quetiapin HEXAL stay in the system after the last dose?

According to the official clinical pharmacology data, the elimination half-life of quetiapine is relatively short: approximately 6 to 7 hours depending on the formulation. The half-life is the time required for half the drug in the body to be eliminated. It typically takes multiple half-lives for the medication to be fully cleared from the system.


Q: Does Quetiapin HEXAL interact with common medications for high blood pressure?

Yes, official drug interaction information advises caution regarding blood pressure medications. Quetiapine may add to the hypotensive effects (blood pressure lowering effects) of antihypertensive agents. This is due to its interaction with certain receptors that regulate peripheral vascular tone.


Q: Is Quetiapin HEXAL associated with any risks to heart health?

Official safety data indicates the medicine is associated with risks to heart health, including an increased heart rate (Tachycardia). An uncommon but serious side effect reported is QT Prolongation, which is a change in the heart's electrical rhythm that is sometimes monitored during treatment.


Q: Can Quetiapin HEXAL be used by people with a history of liver problems?

For individuals with hepatic impairment (liver problems), official guidance states that the medicine's use is conditional and requires starting with a lower dose and proceeding with a slower adjustment schedule. This careful approach is necessary because the drug is primarily processed by the liver.


Q: Is there a best time of day to take Quetiapin HEXAL to minimize side effects?

The recommended time depends on the formulation. Official administration instructions state that the Immediate-Release (IR) tablets are generally taken twice daily. The Prolonged-Release (PR/XR) tablets are intended for once-daily use, preferably in the evening, which may help manage the somnolence side effect by aligning it with sleep.


Q: Does Quetiapin HEXAL affect fertility or reproductive hormones?

Regulatory safety data indicates that quetiapine can cause an increase in the hormone prolactin (Hyperprolactinemia). Elevated prolactin levels may potentially lead to changes in the menstrual cycle in women and may contribute to sexual dysfunction in both men and women.


Q: Can taking Quetiapin HEXAL cause changes in vision?

The official label notes that due to the reported potential for Cataracts (opacification of the eye lens) during long-term treatment, regulatory guidance includes the recommendation for periodic eye examinations. This precaution is advised for patients undergoing chronic use.


Q: Can Quetiapin HEXAL cause constipation or other digestive issues?

Yes, Constipation is listed as a Common adverse reaction in the official safety profile. Additionally, regulatory documents note that in rare cases, more serious digestive issues such as intestinal obstruction have been reported with quetiapine use.


Q: Is it normal for my blood pressure to be a little lower after starting Quetiapin HEXAL?

It is considered common for blood pressure to be affected, especially upon standing. Postural hypotension (lowering of blood pressure when getting up, leading to dizziness) is listed as a Very Common side effect, and is most frequently observed when starting the medication.


Q: Why do some people report feeling restless (akathisia) when they start Quetiapin HEXAL?

Restlessness, sometimes referred to as Akathisia, has been reported in patients treated with antipsychotics and antidepressants, especially during the initial phase of treatment. Regulatory labels note that this symptom should be monitored as it may be associated with underlying changes in mood or potential worsening of condition.


Q: What evidence or research supports the use of Quetiapin HEXAL for its approved conditions?

The use of quetiapine for its approved conditions is supported by evidence derived from structured clinical trials. These trials, including short-term randomized studies and longer maintenance trials, examined symptom patterns and changes in standardized measurements for conditions like schizophrenia and bipolar disorder.

Advertisements

How should Quetiapin HEXAL be stored and disposed of?

Storage Requirements

Quetiapine tablets must be stored at a maximum temperature below 30°C (86°F) to ensure product stability, with U.S. labeling specifying controlled room temperature (20°C to 25°C) is ideal. The product must be kept from freezing and protected from excess heat, moisture, and light.

The medicine should remain in its original container, which must be tightly closed to preserve its quality until the labeled expiration date. It is mandatory to keep the medication out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Quetiapine should not be disposed of via wastewater or household waste without following specific procedures. The preferred method is to take advantage of community drug take-back programs or mail-back options.

If these options are unavailable, the medicine should be mixed with an undesirable substance (such as coffee grounds or kitty litter), placed in a sealed bag or container, and then thrown in the household trash, ensuring all personal information is removed from the original packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quetiapin HEXAL found in:

A-Z Index: